Sakaki, Japan

Kazuo Tokuzaki

This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Kotobuki Pharmaceutical Co Ltd, Astellas Pharma Gmbh. Active years: 2010-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kazuo Tokuzaki. Retrieved from https://idiyas.com/inventor/kazuo-tokuzaki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 


 

Average Co-Inventor Count = 7.3

ph-index = 1

Forward Citations = 13(Granted Patents)


Location History:

  • Sakaki-machi, JP (2010 - 2011)
  • Nagano, JP (2016)

Company Filing History:


Years Active: 2010-2016

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Kazuo Tokuzaki in Cancer Research

Introduction

Kazuo Tokuzaki, an esteemed inventor hailing from Sakaki-machi, Japan, has made significant strides in the field of pharmaceutical innovations. With a remarkable portfolio of three patents, Tokuzaki has focused his research on developing therapeutic agents aimed at treating various forms of cancer. His work underscores the integration of chemistry and medical science, highlighting the essential role of innovative inventions in healthcare.

Latest Patents

Among Tokuzaki's recent accomplishments is a patent for a nitrogen-containing aromatic heterocyclic compound. This groundbreaking compound is designed as a prophylactic and therapeutic agent for bladder cancer. Through extensive studies, Tokuzaki and his team discovered that these compounds exhibit inhibitory actions on FGFR1, FGFR2, and FGFR3, particularly targeting mutant FGFR3. This development presents potential treatment options for various cancers, including lung cancer, hormone therapy-resistant breast cancer, stomach cancer, and especially for mutant FGFR3-positive bladder cancer.

Another notable patent from Tokuzaki involves nitrogen-containing heterocyclic derivatives characterized by 2,6-disubstituted styryl. This innovative compound, along with its pharmaceutically acceptable salts, proves effective as a sodium channel inhibitor. It has shown excellent analgesic effects, particularly in treating neuropathic pain, while minimizing side effects. These inventions represent substantial advancements in cancer treatment and pain management.

Career Highlights

Throughout his illustrious career, Tokuzaki has been associated with prominent companies such as Kotobuki Pharmaceutical Co., Ltd. and Astellas Pharma GmbH. His contributions to these organizations have facilitated groundbreaking research and development in pharmaceutical sciences, allowing for the transition of innovative ideas into practical therapeutic solutions.

Collaborations

Collaboration has been a significant aspect of Tokuzaki's career. He has worked alongside respected colleagues such as Hiroshi Tomiyama and Yoshinori Iwai. These partnerships highlight the collective efforts in scientific research, which are crucial for fostering innovative solutions within the medical landscape.

Conclusion

Kazuo Tokuzaki's inventive spirit and dedication to cancer research exemplifies the impact that innovation can have in the field of medicine. With his recent patents paving the way for new therapeutic possibilities, Tokuzaki serves as an inspiration for future inventors and researchers aiming to make a difference in the world. His work not only contributes to the understanding of complex diseases but also emphasizes the importance of continued innovation in the fight against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…